Prediction and structural equation model of sertraline treatment response in Japanese patients with major depressive disorder

被引:4
|
作者
Nishioka, Gentaro [1 ,2 ,3 ]
Yashima, Hideaki [4 ,5 ]
Kiuchi, Yuji [8 ]
Nakamura, Sumiko [4 ,6 ]
Oyamada, Hideto [7 ]
Ishii, Masakazu [4 ]
Kudo, Ikuo [2 ]
机构
[1] Tokyo Metropolitan Police Hosp, Dept Psychiat, Tokyo 1648541, Japan
[2] Showa Univ, Northern Yokohama Hosp, Dept Psychiat, Yokohama, Kanagawa, Japan
[3] Kawaguchi Hosp, Kawaguchi, Saitama, Japan
[4] Showa Univ, Sch Pharmaceut Sci, Dept Pathophysiol, Tokyo 142, Japan
[5] Gunma Univ Hosp, Dept Pharmaceut, Maebashi, Gunma, Japan
[6] Tokyo Koseinenkin Hosp, Dept Pharmaceut, Tokyo, Japan
[7] Showa Univ, Sch Med, Dept Pharmacol, Tokyo 142, Japan
[8] Showa Univ, Sch Pharmaceut Sci, Ctr Pharmaceut Educ, Tokyo 142, Japan
关键词
major depressive disorder; sertraline treatment response; 5HTTSTin2; personality; recurrence; structural equation model; STAR-ASTERISK-D; LIFE EVENTS; AGED; 75; PERSONALITY; POLYMORPHISM; GENE; TEMPERAMENT; SENSITIZATION; INTEGRATION; RECURRENCE;
D O I
10.1002/hup.2347
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveThe aim of this study was to extract the factors possibly associated with sertraline treatment response and elucidate their interactions and extent of influence. MethodsDemographic state, stress state, personality, and eight genetic polymorphisms at baseline and clinical symptoms at baseline and 8weeks were analyzed and examined by logistic regression and a structural equation model in sertraline treatment study of 96 Japanese patients with major depressive disorder. ResultsNon-responders were associated with higher scores of harm avoidance in Temperament and Character Inventory, higher scores (24) of 17-item Hamilton Rating Scale for Depression at baseline, recurrence, and 12/12 genotype of the serotonin transporter variable number of tandem repeat polymorphism in intron 2 (5HTTSTin2). When we calculated the response index using four factors extracted, the mean response index value of non-responders was significantly higher than that of responders. The symptoms at baseline, personality, recurrence, and polymorphism of 5HTTSTin2 showed significantly direct and positive influences on the symptoms at 8weeks in our final structural equation model with a good model fit. ConclusionConsidering the combination of four factors extracted may be useful for predicting a worse response to sertraline treatment and selecting different treatment other than sertraline. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:576 / 585
页数:10
相关论文
共 50 条
  • [41] Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial
    Ventura, Daniel
    Armstrong, Edward P.
    Skrepnek, Grant H.
    Erder, M. Haim
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (02) : 245 - 250
  • [42] Long-term sertraline treatment of children and adolescents with major depressive disorder
    Rynn, M
    Wagner, KD
    Donnelly, C
    Ambrosini, P
    Wohlberg, CJ
    Landau, P
    Yang, RY
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2006, 16 (1-2) : 103 - 116
  • [43] Response trajectories during escitalopram treatment of patients with major depressive disorder
    Nunez, John-Jose
    Liu, Yang S.
    Cao, Bo
    Frey, Benicio N.
    Ho, Keith
    Milev, Roumen
    Mueller, Daniel J.
    Rotzinger, Susan
    Soares, Claudio N.
    Taylor, Valerie H.
    Uher, Rudolf
    Kennedy, Sidney H.
    Lam, Raymond W.
    [J]. PSYCHIATRY RESEARCH, 2023, 327
  • [44] Early prediction of clinical response in patients with major depressive disorder receiving fluoxetine
    Lin, C. H.
    Lin, K. S.
    Chen, M. C.
    Chou, L. S.
    Chen, C. C.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S335 - S335
  • [45] Sertraline versus venlafaxine XR in major depressive disorder
    Lusicic, Ana
    Jagadheesan, Karuppiah
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (10) : 1618 - 1619
  • [46] Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder
    Parikh, Sagar V.
    Law, Rebecca A.
    Hain, Daniel T.
    Rothschild, Anthony J.
    Thase, Michael E.
    Dunlop, Boadie W.
    DeBattista, Charles
    Forester, Brent P.
    Shelton, Richard C.
    Macaluso, Matthew
    Cogan, Elizabeth S.
    Brown, Krystal
    Lewis, David J.
    Jablonski, Michael R.
    Greden, John F.
    [J]. PSYCHIATRY RESEARCH, 2022, 308
  • [47] Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients
    Firouzabadi, Negar
    Raeesi, Roshanak
    Zomorrodian, Kamiar
    Bahramali, Ehsan
    Yavarian, Ilnaz
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2017, 20 (01): : 1 - 7
  • [48] Improvement of fatigue in patients with major depressive disorder treated with venlafaxine, sertraline, or placebo
    Zhang, HF
    Khandker, R
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 392 - 392
  • [49] Sertraline - A review of its use in the management of major depressive disorder in elderly patients
    Muijsers, RBR
    Plosker, GL
    Noble, S
    [J]. DRUGS & AGING, 2002, 19 (05) : 377 - 392
  • [50] A Combinatorial Pharmacogenomic Algorithm is Predictive of Sertraline Metabolism in Patients With Major Depressive Disorder
    Parikh, Sagar
    Law, Rebecca
    Hain, Daniel
    Rothschild, Anthony
    Thase, Michael
    Dunlop, Boadie
    DeBattista, Charles
    Forester, Brent
    Shelton, Richard
    Macaluso, Matthew
    Cogan, Elizabeth
    Brown, Krystal
    Lewis, David
    Jablonski, Michael
    Greden, John
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 273 - 274